<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676076</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AB1-03</org_study_id>
    <secondary_id>2015-000716-18</secondary_id>
    <nct_id>NCT02676076</nct_id>
  </id_info>
  <brief_title>TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA</brief_title>
  <acronym>TRIMARAN</acronym>
  <official_title>A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 100/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN PATIENTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG ACTING ß2 AGONISTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of CHF 5993 100/6/12.5 µg pMDI&#xD;
      (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus&#xD;
      glycopyrronum bromide) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine&#xD;
      beclometasone dipropionate plus formoterol fumarate), in terms of lung functions parameters&#xD;
      and rate of exacerbations, as well as to assess its safety and some health economics&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2016</start_date>
  <completion_date type="Actual">May 17, 2018</completion_date>
  <primary_completion_date type="Actual">May 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose FEV1 (Forced Expiratory Volume in the first second)</measure>
    <time_frame>at Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of moderate and severe asthma exacerbations rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (Peak of Forced Expiratory Volume in the first second) within 3 hours post-dose</measure>
    <time_frame>at Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in morning PEF (Peak Expiratory Flow)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of severe asthma exacerbations rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Pooled analysis of CCD-05993AB1-03 and CCD-05993AB2-02 trials</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events and Adverse Drug reactions</measure>
    <time_frame>Up to Week 52</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Collection of Health Economics outcomes</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Total use of healthcare resources and absence from work</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1153</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A:&#xD;
CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 100/6 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B :&#xD;
CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12.5 µg</intervention_name>
    <arm_group_label>CHF 5993 100/6/12.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 100/6 µg</intervention_name>
    <arm_group_label>CHF 1535 100/6 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of asthma ≥ 1 year and diagnosed before 40 years old&#xD;
&#xD;
          -  Uncontrolled asthma with double therapy only on medium doses of Inhaled CorticoSteroid&#xD;
             (ICS) in combination with Long-acting beta2 Agonist (LABA) with ACQ-7 (Asthma Control&#xD;
             Questionnaire) ≥1.5&#xD;
&#xD;
          -  Pre-bronchodilator FEV1 &lt;80% of the predicted normal value&#xD;
&#xD;
          -  Positive reversibility test&#xD;
&#xD;
          -  At least 1 documented asthma exacerbation in the previous year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
          -  Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks&#xD;
             prior screening&#xD;
&#xD;
          -  Current or ex-smokers (&gt;= 10 packs year)&#xD;
&#xD;
          -  Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks&#xD;
             prior screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Virchow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facharzt für Innere Medizin Rostock, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 276814</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000716-18/results</url>
    <description>Study Record on EU Clinical Trials Register including results.</description>
  </link>
  <results_reference>
    <citation>Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30.</citation>
    <PMID>31582314</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma, anticholinergics, triple combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.&#xD;
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_description>
    <ipd_access_criteria>Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_access_criteria>
    <ipd_url>https://www.chiesi.com/en/chiesi-clinical-trial-data-request-portal/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

